Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 48.4%

Biodesix, Inc. (NASDAQ:BDSX) saw a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 249,443 shares, a decrease of 48.4% from the January 15th total of 483,591 shares. Approximately 4.5% of the shares of the company are short sold. Based on an average daily trading volume, of 419,332 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily trading volume, of 419,332 shares, the days-to-cover ratio is currently 0.6 days. Approximately 4.5% of the shares of the company are short sold.

Insider Activity

In related news, Director Jack W. Schuler bought 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The stock was purchased at an average cost of $10.96 per share, with a total value of $903,816.40. Following the transaction, the director directly owned 1,463,210 shares of the company’s stock, valued at approximately $16,036,781.60. The trade was a 5.97% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the sale, the chief executive officer owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. The trade was a 7.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have purchased 182,465 shares of company stock valued at $2,084,616 and have sold 7,672 shares valued at $73,576. 30.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Biodesix

Hedge funds and other institutional investors have recently bought and sold shares of the company. DRW Securities LLC bought a new position in Biodesix in the 4th quarter valued at $105,000. Monashee Investment Management LLC raised its position in shares of Biodesix by 12.3% in the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after buying an additional 12,348 shares in the last quarter. Geode Capital Management LLC boosted its stake in Biodesix by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after buying an additional 2,235 shares during the period. Aberdeen Group plc purchased a new position in Biodesix during the fourth quarter worth about $1,784,000. Finally, Oracle Investment Management Inc. purchased a new position in Biodesix during the third quarter worth about $113,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Stock Up 4.7%

Shares of NASDAQ BDSX opened at $10.84 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. The company has a market cap of $86.29 million, a P/E ratio of -1.95 and a beta of 0.67. Biodesix has a 52 week low of $3.44 and a 52 week high of $20.40. The business has a 50-day simple moving average of $8.39 and a two-hundred day simple moving average of $7.98.

Key Headlines Impacting Biodesix

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Reported reduction in month‑end short interest (late Jan) meaningfully lowered days‑to‑cover and near‑term short pressure — a supportive technical factor if sustained.
• Neutral Sentiment: Biodesix will report Q4 and full‑year 2025 results after market close on Feb. 26 and host a 4:30pm ET conference call/webcast for a business update. Investors should listen for revenue, margin, cash‑flow and any guidance or commentary on test uptake (Nodify Lung, IQLung). Earnings Release
• Neutral Sentiment: February short‑interest data show anomalous “0 shares” figures for Feb. 10–12; likely a reporting or exchange/data‑feed error. Treat the zero reports cautiously until corrected by exchanges or data providers.
• Negative Sentiment: CEO Scott Hutton sold 3,559 shares on Feb. 10 (~$10.08 average), reducing his stake ~7.3% — a signal that can unsettle investors even if sales are for personal reasons. CEO Form 4
• Negative Sentiment: Other senior insiders also sold on Feb. 10 (CFO Robin Harper Cowie — 941 shares; Chief Dev. Officer Gary Pestano — 540; CCO Kieran O’Kane — 584; CAO Chris Vazquez — 101). Multiple simultaneous exec sales amplify negative sentiment. CFO Form 4

Wall Street Analyst Weigh In

BDSX has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Biodesix has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.